These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 2274011)
1. [Treatment of acromegaly with octreotide, a synthetic analog of somatostatin with extended action]. Arosio M; Bazzoni N; Faglia G Minerva Endocrinol; 1990; 15(1):29-36. PubMed ID: 2274011 [TBL] [Abstract][Full Text] [Related]
2. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Jallad RS; Musolino NR; Salgado LR; Bronstein MD Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910 [TBL] [Abstract][Full Text] [Related]
3. Treatment of acromegaly with octreotide: effectiveness and tolerability of its pulsatile administration by portable pump. Giusti M; Cuttica CM; Cariola G; Valenti S; Sessarego P; Giordano G Recenti Prog Med; 1995 May; 86(5):189-94. PubMed ID: 7604174 [TBL] [Abstract][Full Text] [Related]
4. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447 [TBL] [Abstract][Full Text] [Related]
5. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Ma P; Wang Y; van der Hoek J; Nedelman J; Schran H; Tran LL; Lamberts SW Clin Pharmacol Ther; 2005 Jul; 78(1):69-80. PubMed ID: 16003295 [TBL] [Abstract][Full Text] [Related]
7. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide]. Laczi F; Magony S; Julesz J Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861 [TBL] [Abstract][Full Text] [Related]
9. Medical management of acromegaly--what and when? Melmed S Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():13-7. PubMed ID: 8372605 [TBL] [Abstract][Full Text] [Related]
10. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. Plöckinger U; Quabbe HJ Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331 [TBL] [Abstract][Full Text] [Related]
11. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. van der Hoek J; van der Lelij AJ; Feelders RA; de Herder WW; Uitterlinden P; Poon KW; Boerlin V; Lewis I; Krahnke T; Hofland LJ; Lamberts SW Clin Endocrinol (Oxf); 2005 Aug; 63(2):176-84. PubMed ID: 16060911 [TBL] [Abstract][Full Text] [Related]
12. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses. Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339 [TBL] [Abstract][Full Text] [Related]
13. [Behavior of the pituitary-thyroid axis in acromegalic subjects during prolonged intermittent and pulsatile treatment with octreotide]. Cuttica CM; Fazzuoli L; Cariola G; Carraro A; Porcella E; Giusti M; Giordano G Recenti Prog Med; 1994 Jan; 85(1):7-12. PubMed ID: 8184183 [TBL] [Abstract][Full Text] [Related]
14. Octreotide for acromegaly treatment: a reappraisal. Giustina A; Karamouzis I; Patelli I; Mazziotti G Expert Opin Pharmacother; 2013 Dec; 14(17):2433-47. PubMed ID: 24124691 [TBL] [Abstract][Full Text] [Related]
15. The effect of octreotide treatment on somatic and psychological symptoms of acromegaly. Ruchala M; Stangierska I; Gurgul E; Stangierski A; Fajfer J; Sowinski J Neuro Endocrinol Lett; 2010; 31(2):265-9. PubMed ID: 20424578 [TBL] [Abstract][Full Text] [Related]
16. [Somatostatin analog (octreotide) in clinical use: current and potential indications]. Meier R; Dierdorf R; Gyr K Schweiz Med Wochenschr; 1992 Jun; 122(25):957-68. PubMed ID: 1621078 [TBL] [Abstract][Full Text] [Related]
17. [Octreotide, analog of somatostatin. Pharmacological properties and therapeutic applications in pituitary endocrine tumors]. Chanson P; Timsit J; Harris AG Presse Med; 1993 Dec; 22(40):2009-16. PubMed ID: 7907419 [TBL] [Abstract][Full Text] [Related]
18. Rebound hypersecretion of GH following octreotide withdrawal due to liver dysfunction in an acromegalic patient. Shimatsu A; Murabe H; Nakamura Y; Usui T Endocr J; 2000 Oct; 47(5):635-8. PubMed ID: 11200946 [TBL] [Abstract][Full Text] [Related]